---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:11:58.822722'
end_time: '2025-12-14T17:20:08.851208'
duration_seconds: 490.03
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: HSPG2
  gene_symbol: HSPG2
  uniprot_accession: P98160
  protein_description: 'RecName: Full=Basement membrane-specific heparan sulfate proteoglycan
    core protein; Short=HSPG; AltName: Full=Perlecan; Short=PLC; Contains: RecName:
    Full=Endorepellin; Contains: RecName: Full=LG3 peptide; Flags: Precursor;'
  gene_info: Name=HSPG2;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881);
    EGF-like_dom. (IPR000742); Ig-like_dom. (IPR007110); Ig-like_dom_sf. (IPR036179)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 24
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P98160
- **Protein Description:** RecName: Full=Basement membrane-specific heparan sulfate proteoglycan core protein; Short=HSPG; AltName: Full=Perlecan; Short=PLC; Contains: RecName: Full=Endorepellin; Contains: RecName: Full=LG3 peptide; Flags: Precursor;
- **Gene Information:** Name=HSPG2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881); EGF-like_dom. (IPR000742); Ig-like_dom. (IPR007110); Ig-like_dom_sf. (IPR036179)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "HSPG2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'HSPG2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **HSPG2** (gene ID: HSPG2, UniProt: P98160) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P98160
- **Protein Description:** RecName: Full=Basement membrane-specific heparan sulfate proteoglycan core protein; Short=HSPG; AltName: Full=Perlecan; Short=PLC; Contains: RecName: Full=Endorepellin; Contains: RecName: Full=LG3 peptide; Flags: Precursor;
- **Gene Information:** Name=HSPG2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881); EGF-like_dom. (IPR000742); Ig-like_dom. (IPR007110); Ig-like_dom_sf. (IPR036179)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "HSPG2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'HSPG2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **HSPG2** (gene ID: HSPG2, UniProt: P98160) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and verification
- Identity confirmed: HSPG2 encodes perlecan (UniProt P98160), a very large basement membrane heparan sulfate proteoglycan with five modular domains and N‑terminal HS chains; the C‑terminus corresponds to domain V, also called endorepellin, which contains laminin G (LG) modules including LG3. Organism: Homo sapiens. Reported domains and modular organization (EGF-like, Ig-like, ConA-like folds) align with recent domain-centric reviews of human perlecan structure and function (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, melrose2024diverseandmultifunctional pages 1-2).

HSPG2/perlecan: key concepts and definitions
- Definition and architecture: Perlecan is a ~470–500 kDa basement membrane-specific proteoglycan with five protein domains (I–V). It bears three HS chains at the N-terminus (domain I), with occasional CS substitutions, and undergoes proteolytic processing that yields bioactive C-terminal fragments, notably endorepellin (domain V) and its LG3 sub-fragment (Jun 2024; https://doi.org/10.1002/pgr2.22; Jul 2024; https://doi.org/10.1002/jsp2.1362) (mongiat2024proteoglycansofbasement pages 3-4, mongiat2024proteoglycansofbasement pages 4-6, melrose2024diverseandmultifunctional pages 1-2).
- Localization: Perlecan is a core scaffold of basement membranes across vasculature and epithelia, and a key component of the pericellular matrix in cartilage, meniscus, tendon/ligament, and intervertebral disc (IVD) (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, melrose2024diverseandmultifunctional pages 1-2).
- Primary molecular functions: (i) structural basement membrane scaffold and PCM stabilizer; (ii) HS-mediated sequestration and presentation of morphogens/growth factors (e.g., FGF family, VEGF, PDGF, BMPs); (iii) regulation of mechanotransduction and mechano‑osmotic signaling in weight‑bearing tissues; (iv) anti‑angiogenic signaling via the processed C‑terminal endorepellin (Jun 2024; https://doi.org/10.1002/pgr2.22; Jul 2024; https://doi.org/10.1002/jsp2.1362) (mongiat2024proteoglycansofbasement pages 4-6, melrose2024diverseandmultifunctional pages 1-2).

Structure, domains, processing, and interactions
- Domain organization: Domain I (HS attachment) drives growth-factor binding/delivery; domain II includes LDL receptor-like features; domain III interacts with select FGFs; domain IV contains multiple Ig-like repeats supporting adhesion and cytoskeletal signaling; domain V (endorepellin) is composed of three LG modules interspersed with EGF-like repeats (Jul 2024; https://doi.org/10.1002/jsp2.1362; Jun 2024; https://doi.org/10.1002/pgr2.22) (melrose2024diverseandmultifunctional pages 1-2, mongiat2024proteoglycansofbasement pages 3-4).
- HS chain biology: The N-terminal HS chains govern high-affinity binding and spatial presentation of HS-binding cytokines and growth factors, modulating their gradients and signaling competence in tissues (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 1-3).
- Proteolytic processing to endorepellin/LG3: Perlecan is proteolytically processed to release endorepellin (domain V) and further to LG3. Endorepellin is an angiostatic matricryptin; LG3 is the principal angiostatic module. BMP‑1/Tolloid-like metalloproteases (and cathepsin L downstream of caspase‑3) mediate cleavage, with a reported specific site between Asn4196 and Asp4197 that yields intact LG3 (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 6-7).

Cellular/extracellular localization and pathway context
- Basement membrane and pericellular niches: Perlecan assembles into vascular/endothelial BMs and avascular cartilaginous PCM, where it stabilizes ECM networks, coordinates receptor signaling, and buffers mechanical loads (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, melrose2024diverseandmultifunctional pages 1-2).
- Receptor and pathway interactions: Perlecan modulates VEGFA/VEGFR2 signaling by localizing VEGF and stabilizing receptor-ligand complexes; supports FGF2–FGFR co‑receptor functions via HS; engages integrins (α2β1, α5β1) and dystroglycan to influence adhesion and downstream kinases; in bone/cartilage/muscle, perlecan contributes to mechanosensing and mechanoresponsive gene programs (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 4-6, mongiat2024proteoglycansofbasement pages 1-3).
- Anti‑angiogenic signaling of endorepellin: Endorepellin exerts dual receptor antagonism by engaging integrin α2β1 and VEGFR2 in endothelial cells, triggering focal adhesion and actin cytoskeleton disassembly and inducing angiostasis at nanomolar concentrations (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 6-7).

Mechanobiology roles and tissue contexts
- Mechanotransduction: In IVD, cartilage, tendon/ligament and other weight-bearing tissues, perlecan’s HS-rich PCM confers mechano‑osmotic transduction that supports cell viability, metabolic buffering in acidic/hypoxic milieus, and remodeling during chondroid metaplasia associated with repair (Jul 2024; https://doi.org/10.1002/jsp2.1362; Jan 2023; https://doi.org/10.1016/j.lfs.2022.121190) (melrose2024diverseandmultifunctional pages 1-2, zhao2023perlecanrolesin pages 1-2).
- Developmental essentiality: Hspg2-null mice exhibit embryonic lethality with severe cardiac and cartilaginous defects, emphasizing perlecan’s nonredundant role in BM integrity and morphogenesis (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731) (lavorgna2023perlecanareview pages 1-2).

Genetics and human disease (2023–2024 updates prioritized)
- Allelic spectrum: Biallelic HSPG2 variants underlie a continuum from Schwartz–Jampel syndrome (SJS; myotonia, chondrodysplasia) through dyssegmental dysplasia (DDSH; lethal neonatal form) to Rolland–Desbuquois-type dyssegmental dysplasia (DDRD; nonlethal). Counts summarized: 44 SJS and 8 DDSH HSPG2 pathogenic variants reported; a 2024 DDRD study identified four pathogenic variants—c.9970G>A (p.G3324R), c.559C>T (p.R187X), c.7006+1G>A, c.11562+2T>G—and a shared founder haplotype of 85,973 bp across five patients, supporting allelism of SJS/DDSH/DDRD and genotype–phenotype correlations (Feb 2024; https://doi.org/10.1038/s10038-024-01229-6) (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2).
- Neuromusculoskeletal and vascular implications: Clinical and experimental syntheses highlight perlecan’s roles in angiogenesis, BBB stability, neuromuscular function, cartilage/bone homeostasis, and sarcopenia/OA associations, with therapeutic exploration of domain V in CNS models (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731) (lavorgna2023perlecanareview pages 1-2).

Cancer biology and endothelial contexts
- Tumor microenvironment: Perlecan’s HS chains can trap and present pro‑angiogenic factors (e.g., FGF2), sustaining endothelial signaling; in contrast, proteolytic remodeling releases endorepellin, which disrupts angiogenic signaling and can reduce tumor neovascularization and growth (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 4-6, mongiat2024proteoglycansofbasement pages 1-3, mongiat2024proteoglycansofbasement pages 6-7).

Cardiovascular and renal findings
- Endothelial dysfunction signature: Secretome profiling under calciprotein particle exposure reports diminished extracellular release of BM components including perlecan/HSPG2 and fibronectin, supporting the use of soluble BM proteins as markers of endothelial stress; these changes co-occur with increased soluble CD59 (Oct 2024; https://doi.org/10.3390/ijms252111382) (melrose2025glycosaminoglycansinstructivebiomolecules pages 10-12).

Applications and real‑world implementations
- Regenerative medicine and biomaterials: Recombinant perlecan domain V/endorepellin is explored as an anti‑angiogenic and pro‑homeostatic additive to biomaterials; perlecan’s domain-specific growth factor–binding and mechano‑osmotic properties are being leveraged in disc and cartilage repair strategies and in vascular biomaterials to modulate endothelial behavior (Jul 2024; https://doi.org/10.1002/jsp2.1362; Jun 2024; https://doi.org/10.1002/pgr2.22) (melrose2024diverseandmultifunctional pages 1-2, mongiat2024proteoglycansofbasement pages 4-6).

Expert opinions and synthesis
- Consensus from 2023–2024 reviews places perlecan as a central BM/PCM hub that integrates structural scaffolding with growth factor presentation and mechanobiology. Its processed C‑terminal endorepellin provides a tunable, context‑dependent switch that counters angiogenic drive by dual targeting VEGFR2 and α2β1 integrin, while N‑terminal HS chains potentiate morphogen signaling. Genetic data in rare skeletal dysplasias provide human evidence for dosage‑sensitive requirements in BM integrity and skeletal development (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jun 2024; https://doi.org/10.1002/pgr2.22; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, mongiat2024proteoglycansofbasement pages 1-3, mongiat2024proteoglycansofbasement pages 4-6, melrose2024diverseandmultifunctional pages 1-2).

Relevant statistics and data
- Variant counts in HSPG2-related disorders: 44 SJS and 8 DDSH pathogenic variants reported; DDRD founder cohort (n=5) sharing an ~86 kb haplotype with four pathogenic variants identified (Feb 2024; https://doi.org/10.1038/s10038-024-01229-6) (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2).
- Endorepellin potency: Recombinant endorepellin exhibits angiostatic activity at nanomolar concentrations and accumulates perivascularly in tumors; LG3 is the principal anti‑angiogenic effector module (Jun 2024; https://doi.org/10.1002/pgr2.22) (mongiat2024proteoglycansofbasement pages 6-7).

Structured summary table
| Category | Key points | Recent sources (Year; DOI/URL) |
|---|---|---|
| Identity / structure | - Five modular domains (I–V)<br>- N-terminal heparan sulfate (HS) chains; occasional CS<br>- C-terminal domain V = endorepellin containing LG modules (LG3) | 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2); 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2) |
| Localization | - Basement membranes (vascular BMs)<br>- Pericellular matrix of cartilage, IVD, tendon<br>- Vascular endothelium/perivascular regions | 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2); 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2) |
| Functions | - Structural BM scaffold and PCM stabilizer<br>- Sequestration/presentation of HS-binding growth factors (FGFs, VEGF, PDGF)<br>- Mechanotransduction / mechano-osmotic regulation | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6); 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2) |
| Angiogenesis | - Endorepellin (domain V) exerts angiostatic activity via dual antagonism of VEGFR2 and integrin α2β1<br>- LG3 module is primary angiostatic effector; active at nanomolar ranges | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 6-7) |
| Processing | - Proteolytic release of endorepellin fragments (LG1-2 and LG3)<br>- BMP-1 / Tolloid-like metalloproteases (and other proteases) mediate cleavage; reported cleavage site near Asn4196–Asp4197 | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 6-7); 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6) |
| Pathways | - VEGFA → VEGFR2 axis (HS modulates VEGF localization/activity)<br>- Integrins: α2β1, α5β1 mediate cell adhesion/signaling<br>- Dystroglycan and FGF2–FGFR interactions for morphogen delivery | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6); 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2) |
| Genetics & disease | - Allelic disorders: Schwartz–Jampel syndrome (SJS), Silverman–Handmaker DDSH, DDRD (Rolland–Desbuquois)<br>- Reported: ~44 pathogenic variants for SJS; 8 for DDSH; 2024 study identified DDRD HSPG2 variants and a shared 85,973 bp founder haplotype | 2024; https://doi.org/10.1038/s10038-024-01229-6 (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2); 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2) |
| Cancer | - Perlecan/HSPG2 modulates tumor angiogenesis and microenvironmental growth-factor availability<br>- Fragmentation (endorepellin) can be angiostatic; intact HS can promote growth-factor signaling | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6); 2023; https://doi.org/10.1016/j.lfs.2022.121190 (zhao2023perlecanrolesin pages 1-2) |
| Cardiovascular / renal | - Perlecan essential for BM integrity in cardiac development and vascular stability<br>- Altered perlecan levels linked to vascular/BM dysfunction and disease contexts | 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2); 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6) |
| Musculoskeletal | - Critical in PCM of cartilage/IVD for osmotic/mechanical buffering<br>- HS-dependent binding/presentation of FGFs and other morphogens supports chondrogenesis and repair | 2024; https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2); 2023; https://doi.org/10.1016/j.lfs.2022.121190 (zhao2023perlecanrolesin pages 1-2) |
| Applications | - Recombinant perlecan domain V / endorepellin explored for anti-angiogenic and regenerative biomaterials<br>- Perlecan-functionalized scaffolds for vascular and cartilage tissue engineering under investigation | 2024; https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6); 2023; https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2) |


*Table: Concise summary table of perlecan (HSPG2) identity, functions, processing, disease links, pathways, and recent sources (2023–2024) to support deeper review and citation.*

Compliance with identification safeguards
- Symbol disambiguation: HSPG2 uniquely corresponds to human perlecan; all cited articles explicitly discuss human perlecan/HSPG2 or mammalian orthologs in the context of human-relevant biology. Domain descriptions (EGF-like, Ig-like, ConA-like folds) align with UniProt and recent domain-centric reviews (May 30, 2023; https://doi.org/10.3389/fphys.2023.1189731; Jul 2024; https://doi.org/10.1002/jsp2.1362) (lavorgna2023perlecanareview pages 1-2, melrose2024diverseandmultifunctional pages 1-2).

Cited sources (selection; URLs and dates)
- Lavorgna TR et al., Frontiers in Physiology, May 30, 2023. Perlecan: a review of its role in neurologic and musculoskeletal disease. https://doi.org/10.3389/fphys.2023.1189731 (lavorgna2023perlecanareview pages 1-2).
- Melrose J & Guilak F., JOR Spine, Jul 2024. Diverse and multifunctional roles for perlecan (HSPG2) in repair of the intervertebral disc. https://doi.org/10.1002/jsp2.1362 (melrose2024diverseandmultifunctional pages 1-2).
- Mongiat M. et al., Proteoglycan Research, Jun 2024. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. https://doi.org/10.1002/pgr2.22 (mongiat2024proteoglycansofbasement pages 4-6, mongiat2024proteoglycansofbasement pages 3-4, mongiat2024proteoglycansofbasement pages 6-7, mongiat2024proteoglycansofbasement pages 1-3).
- Zhao XX et al., Life Sciences, Jan 2023. Perlecan: roles in osteoarthritis and potential treating target. https://doi.org/10.1016/j.lfs.2022.121190 (zhao2023perlecanrolesin pages 1-2).
- Farshadyeganeh P. et al., Journal of Human Genetics, Feb 2024. Dyssegmental dysplasia Rolland–Desbuquois type is caused by pathogenic variants in HSPG2. https://doi.org/10.1038/s10038-024-01229-6 (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2).
- Melrose J., International Journal of Molecular Sciences, Mar 2025. Glycosaminoglycans… https://doi.org/10.3390/ijms26062554 (mechanobiology context; includes statements on perlecan in vascular/cartilage; use cautiously). (melrose2025glycosaminoglycansinstructivebiomolecules pages 10-12)

Limitations
- Some clinically focused 2024–2025 primary data (e.g., specific cancer radioresistance mechanisms; additional cardiovascular/renal genetics) were not available in the present evidence extraction and thus are summarized at pathway level from recent reviews. Where detailed study-level statistics were not present in the extracted evidence, claims are restricted to review-supported mechanistic consensus and explicitly dated/cited (mongiat2024proteoglycansofbasement pages 4-6, mongiat2024proteoglycansofbasement pages 1-3).

References

1. (lavorgna2023perlecanareview pages 1-2): Tessa R. Lavorgna, Timothy E. Gressett, Wesley H. Chastain, and Gregory J. Bix. Perlecan: a review of its role in neurologic and musculoskeletal disease. Frontiers in Physiology, May 2023. URL: https://doi.org/10.3389/fphys.2023.1189731, doi:10.3389/fphys.2023.1189731. This article has 13 citations and is from a poor quality or predatory journal.

2. (melrose2024diverseandmultifunctional pages 1-2): James Melrose and Farshid Guilak. Diverse and multifunctional roles for perlecan (hspg2) in repair of the intervertebral disc. JOR Spine, Jul 2024. URL: https://doi.org/10.1002/jsp2.1362, doi:10.1002/jsp2.1362. This article has 7 citations and is from a peer-reviewed journal.

3. (mongiat2024proteoglycansofbasement pages 3-4): Maurizio Mongiat, Gabriel Pascal, Evelina Poletto, Davion M. Williams, and Renato V. Iozzo. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. Proteoglycan research, Jun 2024. URL: https://doi.org/10.1002/pgr2.22, doi:10.1002/pgr2.22. This article has 13 citations and is from a poor quality or predatory journal.

4. (mongiat2024proteoglycansofbasement pages 4-6): Maurizio Mongiat, Gabriel Pascal, Evelina Poletto, Davion M. Williams, and Renato V. Iozzo. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. Proteoglycan research, Jun 2024. URL: https://doi.org/10.1002/pgr2.22, doi:10.1002/pgr2.22. This article has 13 citations and is from a poor quality or predatory journal.

5. (mongiat2024proteoglycansofbasement pages 1-3): Maurizio Mongiat, Gabriel Pascal, Evelina Poletto, Davion M. Williams, and Renato V. Iozzo. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. Proteoglycan research, Jun 2024. URL: https://doi.org/10.1002/pgr2.22, doi:10.1002/pgr2.22. This article has 13 citations and is from a poor quality or predatory journal.

6. (mongiat2024proteoglycansofbasement pages 6-7): Maurizio Mongiat, Gabriel Pascal, Evelina Poletto, Davion M. Williams, and Renato V. Iozzo. Proteoglycans of basement membranes: crucial controllers of angiogenesis, neurogenesis, and autophagy. Proteoglycan research, Jun 2024. URL: https://doi.org/10.1002/pgr2.22, doi:10.1002/pgr2.22. This article has 13 citations and is from a poor quality or predatory journal.

7. (zhao2023perlecanrolesin pages 1-2): Xiao-Xuan Zhao, Wen-Qing Xie, Wen-Feng Xiao, Heng-Zhen Li, Shinen Naranmandakh, Olivier Bruyere, Jean-Yves Reginster, and Yu-Sheng Li. Perlecan: roles in osteoarthritis and potential treating target. Life Sciences, 312:121190, Jan 2023. URL: https://doi.org/10.1016/j.lfs.2022.121190, doi:10.1016/j.lfs.2022.121190. This article has 7 citations and is from a peer-reviewed journal.

8. (farshadyeganeh2024dyssegmentaldysplasiarolland–desbuquois pages 1-2): Paniz Farshadyeganeh, Takahiro Yamada, Hirofumi Ohashi, Gen Nishimura, Hiroki Fujita, Yuriko Oishi, Misa Nunode, Shuku Ishikawa, Jun Murotsuki, Yuri Yamashita, Shiro Ikegawa, Tomoo Ogi, Eri Arikawa-Hirasawa, and Kinji Ohno. Dyssegmental dysplasia rolland–desbuquois type is caused by pathogenic variants in hspg2 - a founder haplotype shared in five patients. Journal of Human Genetics, 69:235-244, Feb 2024. URL: https://doi.org/10.1038/s10038-024-01229-6, doi:10.1038/s10038-024-01229-6. This article has 2 citations and is from a peer-reviewed journal.

9. (melrose2025glycosaminoglycansinstructivebiomolecules pages 10-12): James Melrose. Glycosaminoglycans, instructive biomolecules that regulate cellular activity and synaptic neuronal control of specific tissue functional properties. International Journal of Molecular Sciences, Mar 2025. URL: https://doi.org/10.3390/ijms26062554, doi:10.3390/ijms26062554. This article has 4 citations and is from a poor quality or predatory journal.

## Citations

1. mongiat2024proteoglycansofbasement pages 1-3
2. mongiat2024proteoglycansofbasement pages 6-7
3. lavorgna2023perlecanareview pages 1-2
4. melrose2025glycosaminoglycansinstructivebiomolecules pages 10-12
5. melrose2024diverseandmultifunctional pages 1-2
6. mongiat2024proteoglycansofbasement pages 4-6
7. zhao2023perlecanrolesin pages 1-2
8. mongiat2024proteoglycansofbasement pages 3-4
9. https://doi.org/10.3389/fphys.2023.1189731;
10. https://doi.org/10.1002/jsp2.1362
11. https://doi.org/10.1002/pgr2.22;
12. https://doi.org/10.1002/jsp2.1362;
13. https://doi.org/10.1002/pgr2.22
14. https://doi.org/10.1016/j.lfs.2022.121190
15. https://doi.org/10.3389/fphys.2023.1189731
16. https://doi.org/10.1038/s10038-024-01229-6
17. https://doi.org/10.3390/ijms252111382
18. https://doi.org/10.3390/ijms26062554
19. https://doi.org/10.3389/fphys.2023.1189731,
20. https://doi.org/10.1002/jsp2.1362,
21. https://doi.org/10.1002/pgr2.22,
22. https://doi.org/10.1016/j.lfs.2022.121190,
23. https://doi.org/10.1038/s10038-024-01229-6,
24. https://doi.org/10.3390/ijms26062554,